Latent syphilis

Summary

Latent syphilis (MONDO:0005822) is a disease and 1 clinical trial. Top therapeutic interventions include linezolid. A subtype of syphilis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	latent syphilis
Mondo ID	MONDO:0005822
EFO	EFO:0007340
MeSH	D013592
DOID	DOID:9531
NCIT	C35056
SNOMED CT	444150000
UMLS	C0039133
MedGen	21056
GARD	0027729
Is cancer (heuristic)	no

Disease family

This is a subtype of syphilis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › syphilis › latent syphilis

Related subtypes (9): bejel, primary syphilis, secondary syphilis, tertiary syphilis, congenital syphilis, yaws, cutaneous syphilis, syphilitic aortitis, chancre

Subtypes (2): latent early syphilis, late latent syphilis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05069974	PHASE3	ACTIVE_NOT_RECRUITING	Alternative Antibiotics for Syphilis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINEZOLID	4	1